Raltegravir One Thousand two hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study
- Registry ID
- EUCTR2017-003470-14
- Source registry
- EUCTR
- Status
- Ongoing
- Phase
- PHASE4
- Sponsor
- FIMABIS Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
- Start date
- 2018-12-12
- Last update
- 2026-08-16
Conditions
- Human Immunodeficiency Virus (HIV) infection
Summary
To explore the efficacy of RAL 1200 mg QD versus DRV/Cb 800-150 mg QD, both in combination with TAF/FTC in subjects infected with HIV naive with a CD4 count <200 cells/μL.
Locations
View on source registry